Cargando…

The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review

BACKGROUND: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients. AIM: The aim of this study was to compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Lisa, Mathibe, Lehlohonolo J., Bangalee, Varsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661289/
https://www.ncbi.nlm.nih.gov/pubmed/34917407
http://dx.doi.org/10.4102/hsag.v26i0.1708
_version_ 1784613336072060928
author Singh, Lisa
Mathibe, Lehlohonolo J.
Bangalee, Varsha
author_facet Singh, Lisa
Mathibe, Lehlohonolo J.
Bangalee, Varsha
author_sort Singh, Lisa
collection PubMed
description BACKGROUND: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients. AIM: The aim of this study was to compare the efficacy of the drug kanamycin, an injectable aminoglycoside, to bedaquiline, a newer oral drug used to treat DR-TB. METHODS: PubMed and Google Scholar, both of which are online databases, were extensively searched using the necessary keywords so that studies that were relevant to the scoping review were retrieved. A data-charting list was developed to extract the needed data for this scoping review. RESULTS: The main findings of the scoping review showed that bedaquiline was highly efficacious in the treatment of DR-TB, and that it was a valuable addition in the treatment of DR-TB. The findings of the study also showed that kanamycin does not have good efficacy against DR-TB. and its use extends the treatment of DR˗TB. CONCLUSION: It stands to reason that bedaquiline replaces kanamycin in the DR-TB drug regimen as it was shown to be more efficacious and patients experienced better treatment outcomes in a shorter period of time. There were also fewer adverse effects associated with bedaquiline as compared to kanamycin. CONTRIBUTION: Bedaquiline-based DR-TB therapy is more efficacious than aminoglycoside-based regimens which include kanamycin.
format Online
Article
Text
id pubmed-8661289
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AOSIS
record_format MEDLINE/PubMed
spelling pubmed-86612892021-12-15 The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review Singh, Lisa Mathibe, Lehlohonolo J. Bangalee, Varsha Health SA Review Article BACKGROUND: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients. AIM: The aim of this study was to compare the efficacy of the drug kanamycin, an injectable aminoglycoside, to bedaquiline, a newer oral drug used to treat DR-TB. METHODS: PubMed and Google Scholar, both of which are online databases, were extensively searched using the necessary keywords so that studies that were relevant to the scoping review were retrieved. A data-charting list was developed to extract the needed data for this scoping review. RESULTS: The main findings of the scoping review showed that bedaquiline was highly efficacious in the treatment of DR-TB, and that it was a valuable addition in the treatment of DR-TB. The findings of the study also showed that kanamycin does not have good efficacy against DR-TB. and its use extends the treatment of DR˗TB. CONCLUSION: It stands to reason that bedaquiline replaces kanamycin in the DR-TB drug regimen as it was shown to be more efficacious and patients experienced better treatment outcomes in a shorter period of time. There were also fewer adverse effects associated with bedaquiline as compared to kanamycin. CONTRIBUTION: Bedaquiline-based DR-TB therapy is more efficacious than aminoglycoside-based regimens which include kanamycin. AOSIS 2021-11-29 /pmc/articles/PMC8661289/ /pubmed/34917407 http://dx.doi.org/10.4102/hsag.v26i0.1708 Text en © 2021. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
spellingShingle Review Article
Singh, Lisa
Mathibe, Lehlohonolo J.
Bangalee, Varsha
The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
title The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
title_full The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
title_fullStr The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
title_full_unstemmed The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
title_short The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
title_sort efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: a systematic scoping review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661289/
https://www.ncbi.nlm.nih.gov/pubmed/34917407
http://dx.doi.org/10.4102/hsag.v26i0.1708
work_keys_str_mv AT singhlisa theefficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview
AT mathibelehlohonoloj theefficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview
AT bangaleevarsha theefficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview
AT singhlisa efficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview
AT mathibelehlohonoloj efficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview
AT bangaleevarsha efficacyofbedaquilineversuskanamycininmultidrugresistanttuberculosisasystematicscopingreview